SCHEMBL8777710

SCHEMBL8777710

Cc1ccc(N2C(=O)C(O)=C(C(=O)c3ccc(C(C)(C)C)cc3)[C@@H]2c2ccc(OC(F)(F)F)cc2)nn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.43
MAPT P10636 2/20 0.43
NCOA2 Q15596 2/20 0.43
TRPV1 Q8NER1 1/20 0.41
RXFP1 Q9HBX9 10/20 0.40
ANXA2 P07355 1/20 0.39
S100A10 P60903 1/20 0.39
MAP3K5 Q99683 1/20 0.39
EPHX2 P34913 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 4/20 0.37
NCOR2 Q9Y618 1/20 0.36
PDE5A O76074 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 3/20 0.36
POLB P06746 1/20 0.36
NCOA1 Q15788 1/20 0.36
ALOX15 P16050 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL932796 1.00 PPARG (0.43) PPARGMAPTNCOA2TRPV1RXFP1
SCHEMBL8777697 1.00 PPARG (0.43) PPARGMAPTNCOA2TRPV1RXFP1
SCHEMBL6116273 0.94 RXFP1 (0.44) PPARGMAPTNCOA2RXFP1ANXA2
SCHEMBL6116048 0.94 RXFP1 (0.43) PPARGMAPTNCOA2TRPV1RXFP1
SCHEMBL933312 0.92 ANXA2 (0.47) PPARGMAPTNCOA2RXFP1ANXA2
SCHEMBL933561 0.92 ANXA2 (0.47) PPARGMAPTNCOA2RXFP1ANXA2
SCHEMBL6115555 0.91 RXFP1 (0.49) PPARGMAPTNCOA2RXFP1ANXA2
SCHEMBL933731 0.91 RXFP1 (0.49) PPARGMAPTNCOA2RXFP1ANXA2
SCHEMBL6115639 0.90 RXFP1 (0.50) PPARGMAPTNCOA2RXFP1MAP3K5
SCHEMBL8777641 0.90 MAPT (0.46) PPARGMAPTNCOA2RXFP1ANXA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120128630-A1 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE VIVALIS (FR) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120128630-A1 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE NAT1, POLM, PYGL PPARG 905/4885MAPT 25/4885NCOA2 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.